Oxytocin

Oxytocin is a real, naturally occurring 9-amino-acid hormone with two very different stories under one name. A synthetic IV/IM version, Pitocin, is a decades-old FDA-approved obstetric drug for inducing labor and controlling postpartum bleeding. A completely separate, unapproved intranasal form is studied for social cognition, bonding and psychiatric conditions like autism and schizophrenia, and the largest recent meta-analysis of that use, pooling 42 trials, found an overall effect indistinguishable from placebo once outlier studies were removed.

Ask about Oxytocin

Research snapshot

CategoryCurrent information
Peptide categoryEndogenous human hormone, synthetic IV/IM version approved; intranasal form unapproved
Primary research interestLabor induction / postpartum hemorrhage control (approved); social cognition, bonding, autism, schizophrenia (intranasal, unapproved)
Highest available evidenceTier 1: decades of clinical evidence for the obstetric use; for intranasal use, a 2026 meta-analysis of 42 RCTs found effect indistinguishable from placebo
Human research availableYes, extensive for both uses
Development statusFully approved pharmaceutical (obstetric); intranasal form remains investigational/unapproved
Regulatory statusFDA-approved (Pitocin, generic) for IV/IM obstetric use; intranasal use for social/psychiatric indications not approved

Technical identity

Technical propertyInformation
Primary nameOxytocin
Alternative namesPitocin, Syntocinon (brand names), OT
Peptide sequenceCys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 (cyclic, disulfide bridge)
Amino-acid length9
Molecular formulaC43H66N12O12S2
Molecular weight≈1007.19 g/mol
CAS Registry Number50-56-6
PubChem CID439302
Peptide classEndogenous neurohypophyseal hormone, oxytocin receptor agonist
Primary biological targetOxytocin receptor (uterus, brain)
Developer / originatorNaturally occurring; synthetic version long-approved (Pitocin)
Development statusApproved prescription drug (IV/IM, obstetric); intranasal form unapproved, investigational

What it is

Oxytocin is a naturally occurring 9-amino-acid human hormone, released by the posterior pituitary, with well-established roles in labor, milk letdown, and social/pair-bonding behavior in animal models. A synthetic version has been an FDA-approved drug for decades, sold generically and under the brand name Pitocin, given intravenously or intramuscularly to induce or augment labor and to control postpartum bleeding.

A separate, much newer research and commercial story concerns intranasal oxytocin, studied for its effects on social cognition, trust, anxiety, and psychiatric conditions including autism spectrum disorder and schizophrenia. This intranasal use has no FDA approval, and it should not be confused with the approved obstetric drug: different route, different population, different evidence base entirely.

Figures in this table summarize dosing described in FDA-approved prescribing information and what has been studied/circulates for the unapproved intranasal use. Their inclusion documents what is reported and does not establish what any individual reader should take.

UseRouteAmountFrequencyEvidence category
Labor induction / postpartum hemorrhage (approved, Pitocin)Intravenous or intramuscularTitrated to uterine response, under clinical monitoringContinuous infusion (labor) or single dose (postpartum)FDA-approved prescribing information
Social cognition / psychiatric research (intranasal)Intranasal20 to 40 IU per doseStudied dosing, varies by trialPublished human RCTs (pooled meta-analysis of 42 trials found overall effect indistinguishable from placebo)
General use, as commonly circulated onlineIntranasal20 to 40 IU per doseOnce or twice dailyCommunity / vendor reported: matches studied dosing, but the studies themselves found little to no effect

Potential benefits and research applications

Labor induction and postpartum hemorrhage control, the FDA-approved obstetric use

Synthetic oxytocin, given IV or IM under labor and delivery monitoring, is a well-established, decades-old treatment to induce or augment labor and to control postpartum bleeding.

Evidence: has been shown extensively in human clinical practice and trials (Tier 1, published human clinical evidence, FDA-approved indication).

Social cognition, trust and bonding, the popular intranasal use with a disappointing recent trial record

Intranasal oxytocin has been extensively studied for effects on trust, social cognition and bonding, generating substantial early enthusiasm. A 2026 meta-analysis of 42 randomized controlled trials found a small, non-significant overall effect that shrank to essentially zero once outlier studies were removed.

Evidence: has not been established. Despite dozens of randomized, placebo-controlled human trials (Tier 1 evidence base), the pooled effect is not distinguishable from placebo.

Autism spectrum disorder and schizophrenia-spectrum conditions, mostly null with one small exception

Intranasal oxytocin has been trialed specifically for autism spectrum disorder and schizophrenia-spectrum disorders. A dedicated autism meta-analysis of 10 RCTs found no significant efficacy for anxiety, repetitive behavior, social function or overall severity; the broader 2026 meta-analysis found a small, significant benefit only in the schizophrenia-spectrum subgroup.

Evidence: has not been established for autism (Tier 1 evidence, null result); a small effect has been shown for schizophrenia-spectrum disorders specifically (Tier 1, published human clinical evidence, small effect size).

The approved use versus the circulating one

The obstetric use is old, well-studied, and dosed precisely by IV infusion titrated to uterine response, under labor and delivery monitoring.

The intranasal, psychiatric/social-cognition use is a different story. A 2026 meta-analysis pooling 42 double-blind randomized controlled trials of intranasal oxytocin versus placebo across autism spectrum disorder, schizophrenia-spectrum disorders, substance use disorders and other mental disorders (total n=1,922) found a small, non-significant overall effect (g=0.17, 95% CI -0.05 to 0.38) with substantial heterogeneity between trials; removing two outlier studies eliminated the heterogeneity and reduced the pooled effect further (g=0.05, 95% CI -0.03 to 0.12), essentially no effect. A significant, small benefit emerged only in the schizophrenia-spectrum subgroup (g=0.12).

Specifically for autism, an earlier systematic review and meta-analysis of 10 randomized controlled trials in adults found no significant efficacy of intranasal oxytocin for anxiety, repetitive behavior, social function or overall severity.

What is not established

Any general benefit of intranasal oxytocin for social cognition, bonding, anxiety or mood in a healthy person taking it outside a clinical trial. The largest recent meta-analysis pooling trials across several psychiatric conditions found an effect close to zero once outlier studies were removed.

Optimal dose, frequency or duration for any of the unapproved intranasal uses; the 2026 meta-analysis specifically found no significant moderation by dose or number of administrations across the pooled trials, meaning the field has not established a dose-response relationship even within its own trial data.

Frequently asked questions

What is oxytocin?

Oxytocin is a naturally occurring 9-amino-acid human hormone with roles in labor, milk letdown and social bonding. A synthetic IV/IM version, Pitocin, is FDA-approved for obstetric use; a separate intranasal form is studied but not approved for social and psychiatric uses.

How does oxytocin work?

It acts on oxytocin receptors in the uterus to stimulate contractions and in the brain to influence social behavior, trust and bonding, mechanisms established mainly in animal models for the social effects.

What dosage has been studied in humans?

The obstetric use is dosed precisely by IV infusion titrated to uterine response. Intranasal trials for social and psychiatric uses generally used 20 to 40 IU per dose.

What dosage commonly circulates online?

Circulating intranasal material describes 20 to 40 IU per dose, once or twice daily, consistent with what most pooled clinical trials actually used. The gap is not dose, it is outcome: that same dosing approach showed an overall effect indistinguishable from placebo in the largest recent meta-analysis.

Has oxytocin been studied in humans?

Extensively, for both uses. The obstetric use has decades of clinical evidence. The intranasal social/psychiatric use has been tested in dozens of randomized controlled trials, with an overall effect close to zero.

Is oxytocin approved for use?

Yes, for obstetric use (Pitocin), given IV or IM. Intranasal oxytocin for social cognition or psychiatric conditions has no FDA approval.

What routes of administration are reported?

The approved obstetric drug is given IV or IM. The unapproved social/psychiatric research and circulating use is intranasal.

Does intranasal oxytocin improve social bonding or trust?

This has not been established for a healthy person outside a clinical trial. The largest recent meta-analysis pooling 42 trials found an overall effect close to zero once outlier studies were removed.

What side effects have been reported?

The obstetric drug has a well-characterized safety profile under clinical monitoring. A comprehensive side-effect profile for self-administered intranasal use was not detailed in the meta-analyses reviewed for this entry.

What remains unknown about oxytocin?

Any general benefit of intranasal oxytocin for social cognition, bonding, anxiety or mood in a healthy person outside a trial, and the optimal dose, frequency or duration for any unapproved intranasal use, since pooled trial data found no significant dose-response relationship.

Bottom line

Oxytocin is two very different stories under one name. As an IV/IM obstetric drug, it is a well-established, FDA-approved treatment with decades of evidence. As an intranasal supplement for social cognition, trust and psychiatric conditions, it has been tested extensively, and the most rigorous recent synthesis of that evidence, a meta-analysis of 42 trials, found an effect indistinguishable from placebo once outlier studies were excluded. The dose people use for that second purpose largely matches what was studied; the studies simply did not find much of an effect.

What circulates E5

Figures reported online. Not dosing, not verified, not endorsed.
Reported useRouteAmount reportedFrequencyReported length
Social bonding/anxiety, generalIntranasal20 to 40 IU per doseOnce or twice dailyOngoing

Circulating intranasal oxytocin material describes 20 to 40 IU per dose, once or twice daily, a range consistent with what most of the pooled clinical trials actually used. The gap here is not dose, it is outcome: the largest recent meta-analysis of that same dosing approach, pooled across 42 trials in several psychiatric conditions, found an overall effect indistinguishable from placebo once outlier studies were excluded. Matching the studied dose does not mean matching a studied benefit.

Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.

Share thisFacebookXEmail